

**Minutes of the June 23, 2017  
Pharmacy & Therapeutics (P&T) Committee Meeting  
South Dakota Department of Social Services, Division of Medical Services**

**Members Present**

Dana Darger, Mikal Holland, Bill Ladwig, Michelle Baack, Kelley Oehlke, Richard Holm, Lenny Petrik, James Engelbrecht

**DSS Staff Present**

Mike Jockheck

**Administrative Business**

The meeting was called to order by Darger at 1:00 P.M. The minutes of the December meeting were presented. Ladwig made a motion to approve, Holm seconded the motion. The motion was approved unanimously.

**Prior Authorization Update (PA) and Statistics**

The committee reviewed the PA activity for April 2017. There were a total of 3,071 PAs processed in the month of April, with 99.32% of those requests responded to in less than eight hours. There were 2,166 requests (71%) received electronically and 905 requests (29%) received by fax.

**Analysis of the Top 15 Therapeutic Classes and Drug Spend**

The committee reviewed the top 15 therapeutic classes by total cost of claims from 01/01/17 – 03/31/17. The top five classes were antipsychotic agents, respiratory and CNS stimulants, insulins, amphetamines, and anticonvulsants, misc. The top 15 therapeutic classes make up 38.32% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 15.08% of total claims. In response to a request at the last meeting, a list of insulin products included in the insulin AHFS class was given. The drug spend and medication for hemophilia was also discussed.

**Opioid Strategies for Management Review**

The committee has requested a report that will review patients taking opiates and determine how many patients are at each MME breakpoint. There was also discussion of sending out educational information regarding MME's to prescribers of opiates. Further discussion of opioid utilization management will be added to the agenda for future meetings. There was no public comment.

### **Topical Immunomodulators Review**

A review of indications, cost comparisons and summary of criteria from other states was given for the topical immunomodulators, including Elidel, Protopic and Eucrisa. There was no public comment.

### **Dupixent Review**

Dupixent information was presented for review. Kathryn Munoz, representative from Sanofi-Genzyme, spoke regarding the indications and use of Dupixent. The committee requested that a PA form be developed. The PA form will contain the following: prescribed in consultation with a dermatologist or allergist/immunologist, require diagnosis, require a trial of a first-line agent and be age appropriate. Bakke made a motion that the PA form be brought back for review during the September meeting. Ladwig seconded. The motion passed unanimously.

### **Insulin Review**

At the March meeting the committee requested a brief overview of available insulin products. Deidra Van Gilder, PharmD, from South Dakota State University College of Pharmacy gave a brief overview of available insulin products. Joseph Loftus, MD, representative from Novo Nordisk spoke.

### **Review of Codeine and Tramadol Utilization**

The recent FDA Drug Safety Communication regarding the use of codeine and tramadol in patients younger than 12 was reviewed. State utilization of these products was discussed. The committee considered ways to limit utilization in this population. It was decided to identify the number of providers that had prescribed to this group of patients and discuss at the September meeting. There was no public comment.

### **Xyrlix Kit Review**

Xyrlix information was presented for review. The committee requested that a PA form be developed. The PA form will contain the following: require a trial of diclofenac gel. There was no public comment. Ladwig made a motion that the PA form be brought back for review during the September meeting, as well as information as to how other states are handling this medication. Bakke seconded. The motion passed unanimously.

### **Zorvolex/Zipsor/Cambia Review**

Zorvolex, Zipsor and Cambia information was presented for review. The committee requested that a PA form be developed. The PA form will contain the following: require a trial of a generic diclofenac product. There was no public comment. Holm made a

motion that the PA form be brought back for review during the September meeting. Bakke seconded. The motion passed unanimously.

Jockheck addressed the committee, explaining that a new member was needed. There was discussion regarding about whether the candidate should be a pharmacist or physician and if it would be beneficial to the committee to have a provider with a specialty. Jockheck asked that all potential candidates be directed to his office for instructions on how to proceed with applying for the position.

The next meeting is scheduled for 09/29/2017. Holland motioned to adjourn. Holm seconded. The meeting adjourned at 2:50 P.M.